Pantherna Therapeutics

What Pantherna Therapeutics does

Pantherna Therapeutics GmbH is a pre-clinical-stage German biopharmaceutical company focused on advanced lipid nanoparticle (LNP) technologies for the targeted, cell-selective delivery of mRNA-based therapeutics. Founded in the mid-to-late 2010s and headquartered in Hennigsdorf with R&D operations on the Bayer Pharma Campus in Berlin, the company builds its offering around two proprietary, trademarked platforms: PTXmRNA® (UTR-optimized expression cassettes with tailored 5′- and 3′-UTRs and optional secretion signals for tissue-specific protein expression with minimized immune activation) and PTXΔLNP® (LNP formulations with tunable surface charge — anionic, neutral, cationic — designed to escape the liver tropism that constrains conventional LNPs). The integrated stack supports both ex vivo and in vivo applications, including emerging in vivo CAR-T strategies, with lead candidate PAN004 positioned for acute respiratory distress syndrome (ARDS).

Pantherna monetizes its technology predominantly through a B2B partnership and licensing model rather than through product sales. Revenue streams include platform technology licensing to pharmaceutical and biotech partners, research collaborations and technology evaluation agreements (e.g., Astellas, Bayer, Evaxion, BioSpring, Kither Biotech, Loma Therapeutics, TQ Therapeutics, ARCALIS), and contract manufacturing arrangements (WACKER Biotech as GMP producer for PAN004). Customers are primarily enterprise pharmaceutical and biotech companies plus academic research institutions, reached via enterprise field sales led by the CEO alongside event-driven outreach (BIO-Europe, mRNA Health Conference, Biovaria). Pricing and contract values are not publicly disclosed.

Effective June 1, 2026, Pantherna became a wholly owned subsidiary of T-CURX GmbH, integrating its LNP-mRNA delivery platform with T-CURX's non-viral transposon-based CAR-T technology. The combined entity reports ~35 employees and a portfolio of 16 patent families, with prior ownership held by High-Tech Gründerfonds (HTGF), Riesner Verwaltungs GmbH, Prof. Detlev Riesner, the European Investment Fund, and the State of Brandenburg, alongside EFRE public grant funding (EUR 2.2M).

Name

Pantherna Therapeutics

Legal name

Pantherna Therapeutics GmbH

Website

https://pantherna-therapeutics.com

Company type

Private

Founded year

2017

Operating status

Acquired

Headcount range

11–50 employees

Short description

Pantherna Therapeutics is a German pre-clinical biopharmaceutical company developing proprietary LNP-mRNA delivery platforms (PTXmRNA® and PTXΔLNP®) for tissue-specific therapeutics, including in vivo CAR-T and lead candidate PAN004 for ARDS, partnering with pharmaceutical and biotech firms; it became a wholly owned subsidiary of T-CURX in June 2026.

Ownership category

akta.pro rank

Product category

mRNA Therapeutics Delivery Technology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

akta.pro secondary industries

RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry) (HLAAADAE), RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification) (HLAAADAH), RNA Therapeutics Safety & Immunogenicity (innate immune activation, tox, off-target) (HLAAADAI)

Keywords

• MRNA therapeutics
• Lipid nanoparticle delivery
• Cell-selective delivery
• Non-viral CAR-T
• LNP drug delivery

Headquarters

HQ city

Hennigsdorf

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

1. Therapeutic Development & Licensing: Development of proprietary mRNA-LNP therapeutic candidates (e.g., PAN004 for ARDS) with potential for licensing to pharmaceutical partners
2. Technology Platform Partnerships: Research collaborations and technology evaluation agreements with pharmaceutical and biotech companies for use of proprietary PTXmRNA® and PTXΔLNP® platforms
3. Platform Technology Licensing: Licensing of proprietary LNP technologies to CDMOs and pharmaceutical partners for manufacturing and development purposes

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Pantherna Therapeutics develops proprietary lipid nanoparticle (LNP) formulations and engineered mRNA constructs (PTXmRNA® and PTXΔLNP® platforms) for targeted, cell-selective delivery of nucleic acid therapeutics, supporting both ex vivo and in vivo applications including in vivo CAR-T strategies. Its lead preclinical candidate PAN004 targets Acute Respiratory Distress Syndrome (ARDS), and the technology is monetized via research collaborations, technology evaluation agreements, licensing, and contract manufacturing partnerships with pharmaceutical and biotech companies.

Differentiator

Problem solved

Functional benefit

Products and services

• PTXmRNA® Platform Proprietary mRNA expression construct platform with uniquely tailored 5´/3´-UTRs and optional secretion signals, enabling potent tissue-specific protein expression with minimized immune activation for therapeutic applications. Licensed and evaluated by pharmaceutical partners including Bayer, Astellas, BioSpring, PROVIREX, and TQ Therapeutics.
• PTXΔLNP® / PTX_LNP Platform Advanced lipid nanoparticle formulations enabling targeted, cell-selective delivery of mRNA beyond the liver (overcoming conventional LNP liver tropism), supporting ex vivo and in vivo applications including in vivo CAR-T strategies; offered for research collaboration, evaluation, and licensing.
• PAN004 (mRNA therapeutic for ARDS) Pantherna's lead preclinical mRNA-LNP therapeutic candidate targeting Acute Respiratory Distress Syndrome (ARDS), advanced via a contract manufacturing partnership with WACKER Biotech for GMP production of preclinical material.

Quantifiable outcome

• PTXmRNA technology shown effective across all tissues and cell types in vitro and in vivo
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

16 partnerships are on record, tiered core, major and minor.

• T-CURX GmbHcoreStrategic or Co-development Partner · 1 June 2026T-CURX acquired Pantherna Therapeutics as a wholly owned subsidiary to leverage complementary expertise in non-viral transposon-based CAR-T technology and LNP-mRNA delivery platforms. Combined entity positioned as leading next-generation CAR-T player with both proprietary CAR-T and LNP technologies under one roof. Pantherna's PTXmRNA® and PTXΔLNP® platforms potentiate T-CURX's in vivo CAR-T strategies.
• Heinrich Heine University Düsseldorf (HHU) & University Hospital Düsseldorf (UKD)majorStrategic or Co-development Partner · 11 February 2026Collaboration with Etzkorn Lab at HHU and Lang lab at UKD focusing on in vivo pharmacological use of PTXDLNP® formulation technology with RNA-cleaving DNAzymes. Part of 3 Mio. € 'DNAmazing' Go Bio-next project.
• Kither Biotech S.r.l.coreStrategic or Co-development Partner · 8 January 2026Strategic research collaboration combining Pantherna's LNP mRNA delivery platform with Kither's clinical-stage peptide therapeutic KIT2014 for synergistic approaches addressing genetic lung diseases. Dual-mechanism strategy combining mRNA-based protein restoration with peptide functional enhancement.
• ARCALIS, Inc.majorTechnology or Integration · 16 October 2025Research collaboration granting ARCALIS access to PTX_LNP technology to explore and evaluate selected LNP formulations for potential integration into ARCALIS's service portfolio for European and Asian mRNA-LNP markets.
• Loma TherapeuticsmajorStrategic or Co-development Partner · 1 September 2025Collaboration combining Loma's HPV immunotherapy technology with Pantherna's non-viral LNP delivery platform to accelerate development of next-generation immunotherapies.
• TQ Therapeutics GmbHmajorStrategic or Co-development Partner · 25 October 2024Research collaboration to advance ultra-short extracorporeal cell therapy process combining Pantherna's PTX-LNPs with TQ's point-of-care cellular therapy generation platform for enhanced CAR-T cell production.
• Bayer AGmajorTechnology or Integration · 26 September 2024Research collaboration investigating novel LNP-carriers for future mRNA therapies outside the liver. Combined expertise to identify novel LNP formulations surpassing conventional neutral LNPs for desired pharmacological outcomes.
• BioSpring GmbHmajorTechnology or Integration · 1 August 2024Strategic cooperation in genome editing field focusing on development and licensing of therapeutic mRNA molecules based on PTXmRNA® technology for genome editing applications. BioSpring is world's leading provider of RNA for genome editing.
• Wacker Biotech GmbHcoreImplementation/ SI/ Consulting Partner · 5 April 2024Intensified collaboration for development and production of mRNA biopharmaceuticals. WACKER's mRNA competence center in Halle produces PAN004 active ingredient for ARDS treatment. Pantherna is WACKER's first partner to receive preclinical material from new production plant.
• University Medicine Rostock (UMR)minorStrategic or Co-development Partner · 7 June 2023Collaboration with Prof. Fuchsluger's laboratory to analyze suitability of PTXDLNP® formulations for non-viral delivery of target mRNAs for treatment of eye diseases related to corneal endothelial dysfunction.
• Evaxion Biotech A/SmajorTechnology or Integration · 8 February 2023Preclinical collaboration demonstrating tumor neoantigens identified by Evaxion's AI platform PIONEER combined with Pantherna's PTXΔLNP® and PTXmRNA® platforms achieved complete tumor growth inhibition in preclinical model.
• Astellas Pharma Inc.coreTechnology or Integration · 4 October 2022Expanded technology evaluation agreement for research on mRNA-based regenerative medicine using direct reprogramming. Expanded from initial 2021 agreement to include new target organs. Pantherna provides PTXmRNAs and Astellas contributes drug discovery capabilities.
• Charité – Universitätsmedizin BerlinmajorStrategic or Co-development Partner · 5 September 2022Research collaboration exploring mRNA therapies for autoimmune diseases using PTX-mRNA and PTX-LNP technologies. Focus on therapeutic vaccination for neurological conditions like Neuromyelitis optica spectrum disorders (NMOSD).
• Astellas Innovation Management LLCmajorTechnology or Integration · 12 June 2020Initial technology evaluation agreement investigating efficiency and specificity of Pantherna's PTXΔLNPs to deliver PTXmRNAs by different routes of administration.
• PROVIREX Genome Editing Therapies GmbHmajorTechnology or Integration · 26 March 2020Development of lipid-based delivery systems for mRNA-directed genome editing of lymphocytes using PTXxLNP technology for non-viral delivery of proprietary antiviral genome editing tool Brec1 for HIV treatment.
• Helmholtz-Zentrum Geesthacht - Institute of Biomaterial ResearchminorImplementation/ SI/ Consulting Partner · 1 March 2018Contracted research agreement where institute generates and functionally evaluates mRNA constructs designed by Pantherna. Located in Teltow, Germany.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• BioNTech: Global mRNA therapeutics leader developing both mRNA platforms and LNP delivery systems for vaccines and oncology. Comparable as the dominant player in the same mRNA-LNP space, though at vastly greater scale and clinical maturity.
• Moderna: Leading mRNA therapeutics and vaccines company with proprietary LNP delivery technology. Directly comparable technology stack but operating at commercial scale across multiple therapeutic areas.

Direct peers

• CureVac: German-headquartered mRNA therapeutics company developing mRNA constructs and delivery technologies for vaccines and oncology. Closely comparable as a Europe-based mRNA platform peer, though focused on different LNP approaches.
• Ethris: Germany-based biotech developing stabilized mRNA (SNaP LNP) for lung and respiratory diseases. Closely comparable in stage, geography, technology focus on mRNA + LNP delivery, and respiratory indication overlap (ARDS).
• Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary LNP delivery platform targeting liver and non-liver tissues. Directly comparable in mRNA-LNP platform approach with similar extrahepatic delivery focus.
• Acuitas Therapeutics: LNP technology specialist providing delivery systems for mRNA therapeutics, including partnership with BioNTech/Pfizer for COVID-19 vaccine. Comparable as a pure-play LNP delivery platform peer.
• Genevant Sciences: LNP delivery technology company developing lipid nanoparticle platforms for nucleic acid delivery. Directly comparable as an LNP-focused platform peer serving the same pharmaceutical and biotech partners.

Emerging players

• T-CURX: Parent company of Pantherna since June 2026, developing non-viral transposon-based CAR-T therapies. Comparable as a combined cell therapy + LNP platform with shared therapeutic focus on next-generation CAR-T.
• Evaxion Biotech: AI-driven immunology company developing neoantigen-based immunotherapies, partnered with Pantherna for in vivo delivery of tumor neoantigens using PTXΔLNP® + PTXmRNA®. Comparable as an emerging immunotherapy platform leveraging Pantherna's delivery technology.
• Kither Biotech: Clinical-stage peptide therapeutics company focused on respiratory/lung diseases (KIT2014), partnered with Pantherna for mRNA-LNP delivery. Comparable as a partnered emerging biotech combining complementary mechanisms for lung indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pantherna-therapeutics-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pantherna Therapeutics